An Extension Study of AGT-181-102 Evaluating Safety and Glycosaminoglycans (GAGs) in Adult Patients With Hurler-Scheie or Scheie Syndrome Who Have Completed 8-Weeks of Dosing With AGT-181 in Study AGT-181-102

Trial Profile

An Extension Study of AGT-181-102 Evaluating Safety and Glycosaminoglycans (GAGs) in Adult Patients With Hurler-Scheie or Scheie Syndrome Who Have Completed 8-Weeks of Dosing With AGT-181 in Study AGT-181-102

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs AGT 181 (Primary)
  • Indications Mucopolysaccharidosis I
  • Focus Adverse reactions
  • Sponsors ArmaGen Technologies
  • Most Recent Events

    • 23 Jan 2017 Time frame of primary endpoint has been changed from 26 weeks to 104 weeks (2 years).
    • 23 Jan 2017 Planned number of patients changed from 9 to 3.
    • 23 Jan 2017 Planned End Date changed from 1 Apr 2017 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top